Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Green3Bio, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04711161
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
News
No news found